Literature DB >> 13797091

Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

D W BARRITT, S C JORDAN.   

Abstract

Entities:  

Keywords:  ANTICOAGULANTS/therapy; PULMONARY EMBOLISM/therapy

Mesh:

Substances:

Year:  1960        PMID: 13797091     DOI: 10.1016/s0140-6736(60)92299-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  208 in total

1.  Hospital-based approach to the management of venous thromboembolism.

Authors:  F A Anderson
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Anticoagulants for deep venous thrombosis.

Authors:  D K Cundiff
Journal:  J R Soc Med       Date:  2001-11       Impact factor: 5.344

Review 3.  Anticoagulation in patients with thromboembolic disease.

Authors:  R C Tait
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 4.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

5.  Diagnosing pulmonary embolism.

Authors:  N W Morrell; W A Seed
Journal:  BMJ       Date:  1992-05-02

6.  PHENINDIONE SENSITIVITY.

Authors:  A HOLLMAN; H O WONG
Journal:  Br Med J       Date:  1964-09-19

7.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1964-02       Impact factor: 23.059

8.  PULMONARY EMBOLISM.

Authors:  M T MORRELL; S C TRUELOVE; A BARR
Journal:  Br Med J       Date:  1963-10-05

9.  ACUTE RENAL FAILURE IN PHENINDIONE SENSITIVITY.

Authors:  K SMITH
Journal:  Br Med J       Date:  1965-07-03

Review 10.  [Therapy and secondary prevention of venous thromboembolism with vitamin K antagonists].

Authors:  R M Bauersachs
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.